The Calgary company SemBioSys are causing a stir in the Canadian diabetes industry. Following their recent announcement that they could produce insulin at a commercially viable level in a genetically modified safflower, the company have attracted a stream of potential investors .
The companies burning up the SemBioSys phone line are all looking for partnership, to bring the pioneering insulin product to the market . The chief executive, Mr. Andrew Baum, reported: “Some of the usual suspects and not-so-usual suspects have been calling us up saying when can we get together and talk about how we might work together. I characterize the partnership process as kind of like dating. To this point I would say we’ve been flirting with potential partners … I think we’re going to start dating. Hopefully we’ll get married once we announce our pre-clinical data .”
Baum also made the point that the Canadian diabetes companies could play a large part in the next wave of diabetes treatment developments.
The Canadian diabetes situation is increasing rapidly, with a projected population increase to 2.7 million by 2010. Mr. Rodrigues, the chairman of the national research council for the Canadian Diabetes Associatio, called the emerging Canadian diabetes market ‘huge.’

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…